Clinical Scorecard: Euretina 2025 Opens With Record Attendance
At a Glance
| Category | Detail |
|---|---|
| Condition | Retinal Care |
| Key Mechanisms | Artificial Intelligence in clinical practice and trials |
| Target Population | Patients with age-related macular degeneration (AMD) and retinal diseases |
| Care Setting | Ophthalmology clinics and research institutions |
Key Highlights
- Record attendance of over 10,000 participants at the 25th Euretina Congress
- Keynote by Ursula Schmidt-Erfurth on AI's role in retinal care
- Awards presented for significant research contributions in retinal medicine
- Recognition of the FEBOS-Retina certification program
Guideline-Based Recommendations
Diagnosis
- Utilize AI tools for population screening and clinical trials in AMD
Management
- Implement guided treatment strategies for geographic atrophy using AI
Monitoring & Follow-up
- Apply deep phenotyping of OCT biomarkers for ongoing assessment
Risks
- Consider physiological risk factors for retinopathy of prematurity progression
Patient & Prescribing Data
Individuals with retinal diseases, particularly AMD
Anti-VEGF therapy impacts neurodevelopment in retinopathy of prematurity
Clinical Best Practices
- Incorporate AI in routine retinal assessments and management plans
- Engage in continuous education through certifications like FEBOS-Retina
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.